Search hospitals > Kansas > Wichita
Cancer Center of Kansas - Wichita
Claim this profileWichita, Kansas 67214
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
574 reported clinical trials
4 medical researchers
Summary
Cancer Center of Kansas - Wichita is a medical facility located in Wichita, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. Cancer Center of Kansas - Wichita is involved with conducting 574 clinical trials across 510 conditions. There are 4 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Dennis F. Moore, Shaker Dahkil, MD, and Bassam I. Mattar, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Shaker Dakhil, M.D.Cancer Center of Kansas - Wichita5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
81 reported clinical trials
168 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
26 reported clinical trials
72 drugs studied
Shaker Dahkil, MDCancer Center of Kansas4 years of reported clinical research
Studies Cancer
Studies Breast Cancer
1 reported clinical trial
4 drugs studied
Bassam I. Mattar, MDCancer Center of Kansas3 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
1 reported clinical trial
2 drugs studied
Clinical Trials running at Cancer Center of Kansas - Wichita
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Bladder Carcinoma
Cancer
Colorectal Cancer
Bladder Cancer
Renal Cell Carcinoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center of Kansas - Wichita?
Cancer Center of Kansas - Wichita is a medical facility located in Wichita, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. Cancer Center of Kansas - Wichita is involved with conducting 574 clinical trials across 510 conditions. There are 4 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Dennis F. Moore, Shaker Dahkil, MD, and Bassam I. Mattar, MD.
Where is Cancer Center of Kansas - Wichita located?
The Cancer Center of Kansas is located at 818 N. Emporia, Suite 403, Wichita, KS 67214, with multiple locations throughout Wichita.
Who should I call to ask about financial aid or insurance network?
The Cancer Center of Kansas complies with Federal civil rights laws, ensuring no discrimination based on race, color, national origin, age, disability, or sex. For general inquiries, please call 316-262-4467. For financial assistance related to medical bills, contact the University of Kansas Health System at 913-588-5820.
What insurance does Cancer Center of Kansas - Wichita accept?
The Cancer Center of Kansas - Wichita accepts a wide range of insurance plans, including commercial insurance, Medicare, Medicare Part C, Medicaid, U.S. Department of Veterans Affairs, and TRICARE plans. For specific coverage details, it is recommended to contact an Oncology Information Specialist at the hospital or Outpatient Care Center.
What awards or recognition has Cancer Center of Kansas - Wichita received?
The Cancer Center of Kansas in Wichita, Kansas, is a distinguished recipient of the 2018 and 2016 Favorite for Best Hospital for Cancer Care in Wichita Kansas Reader's Choice Awards. It was also named the 2016 Employer of the Year by CLASS LTD for its commitment to employing individuals with intellectual or other developmental disabilities. Furthermore, the center earned recognition as a 2016 Admirable Statewide Partner for its outstanding dedication.